Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

We expect the drug to reach peak sales of over $40 billion ... Merck has executed reasonably well. While Merck hasn’t made many major acquisitions over the recent past, the Acceleron deal ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Yuhan's Lazcluze, licensed by Johnson & Johnson, has made history as the first Korea-developed novel cancer drug to be approved by the FDA. Merck has optioned in on one Kelun Biotech antibody-drug ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...